Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683396 · ClinicalTrials.gov registry record · Phase 2
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
A Phase 2 study, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01683396 is a Phase 2 study that has completed, run by Xoma (US). The registered enrollment target is 87 participants.
The verdict
NCT01683396, a Phase 2 study, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of active inflammatory, erosive osteoarthritis of the hand.
Interventions
- DRUG Placebo
- DRUG gevokizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01683396
The ClinicalTrials.gov registry entry for NCT01683396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01683396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01683396 about?
NCT01683396 is a clinical study titled "Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand". The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of active inflammatory, erosive osteoarthritis of the hand.
What is the current status of trial NCT01683396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2012-07. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01683396?
The interventions under investigation include: Placebo (DRUG), gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01683396?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.